Lupin's Indian plant faces FDA GMP scrutiny
This article was originally published in Scrip
Executive Summary
The US FDAhas listed 15 observations in an inspection report (FDA-483) following a good manufacturing practices (GMP) audit at Lupin's facility in Madideep, India. A Form 483 is a notice of inspectional observations and lists deficiencies in the quality system.